Akèy › Kansè Ezofajyen › Virginia › Arlington
Etid klinik pou Kansè Ezofajyen nan Arlington, VA
11 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Ap rekriteFaz 1
- Site 04, Fairfax · 11 mi lwen
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Ap rekriteFaz 1
- Inova Schar Cancer Infusion Pharmacy, Fairfax · 11 mi lwen
- Inova Schar Cancer, Fairfax · 11 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, Fairfax · 11 mi lwen
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Clinical Trial Site, Fairfax · 11 mi lwen
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax · 11 mi lwen
Etid Kansè Ezofajyen nan lòt vil
- Houston, TX36 etid
- Boston, MA23 etid
- New York City, NY22 etid
- Nashville, TN19 etid
- St. Louis, MO17 etid
- Pittsburgh, PA15 etid
- Los Angeles, CA15 etid
- Baldwin Park, CA14 etid
- Grand Rapids, MI14 etid
- Philadelphia, PA13 etid
- San Antonio, TX12 etid
- Rochester, MN11 etid
Lòt etid nan Arlington
- Kansè Poumon ki pa ti selil104 etid
- Kansè Metastatik53 etid
- Kansè kolorektal52 etid
- Kansè (tout kalite)48 etid
- Kansè nan tete47 etid
- Kansè ovè46 etid
- Kansè poumon41 etid
- Kansè Endomèt39 etid
- Kansè pankreyas33 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
- Kansè poumon selil ti23 etid
- Kansè lestomak20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.